Ziopharm Oncology Announces FDA Fast Track Designation for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Recurrent Glioblastoma

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing